SCHEMBL1964210

SCHEMBL1964210

CC(C)(C)OC(=O)N(Cc1ccccc1F)n1cccc1

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
RIPK1 Q13546 3/20 0.46
ALDH1A1 P00352 2/20 0.42
KDM4E B2RXH2 1/20 0.42
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
ATM Q13315 1/20 0.40
CTSS P25774 1/20 0.39
CTSK P43235 1/20 0.39
TSPO P30536 1/20 0.38
GAA P10253 1/20 0.38
RAB9A P51151 1/20 0.38
GPR119 Q8TDV5 1/20 0.38
PTPN1 P18031 1/20 0.36
MAPT P10636 2/20 0.36
TP53 P04637 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
PKM P14618 1/20 0.36
GFER P55789 1/20 0.36
LIPE Q05469 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1964518 0.87 RIPK1 (0.46) RIPK1PKM
SCHEMBL1965415 0.86 GPR119 (0.36) RIPK1ALDH1A1KDM4ECTSSCTSK
SCHEMBL1964559 0.84 LMNA (0.44) ALDH1A1KDM4EATMGAA
SCHEMBL1966140 0.84 NPC1 (0.39) ALDH1A1MEN1KMT2ARAB9AMAPT
SCHEMBL1964950 0.82 AKT1 (0.46) RIPK1MEN1KMT2ACTSSRAB9A
SCHEMBL1966131 0.81 KDM1A (0.42) RIPK1MEN1KMT2A
SCHEMBL1965544 0.78 RIPK1 (0.47) RIPK1ALDH1A1MEN1KMT2ACTSS
SCHEMBL21987976 0.77 RIPK1 (0.50) RIPK1ALDH1A1KDM4EMEN1KMT2A
SCHEMBL1966228 0.76 MEN1 (0.41) ALDH1A1KDM4EMEN1KMT2ASMN1; SMN2
SCHEMBL1965400 0.76 GAA (0.40) ALDH1A1KDM4EMEN1KMT2AGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2334682-B1 PYRROLO [ 1, 2 -B] PYRIDAZINE DERIVATIVES AND THEIR USE AS HIF MODULATORS FIBROGEN INC (US) 2017-10-04 EP disclosed
US-8217043-B2 Compounds and methods for their use FIBROGEN, INC. (US) 2012-07-10 US disclosed
EP-2334682-A1 PYRROLO [ 1, 2 -B] PYRIDAZINE DERIVATIVES AND THEIR USE AS HIF MODULATORS Fibrogen, Inc. (US) 2011-06-22 EP disclosed
WO-2010022240-A1 PYRROLO [ 1, 2 -B] PYRIDAZINE DERIVATIVES AND THEIR USE AS HIF MODULATORS FIBROGEN, INC. (US) 2010-02-25 WO disclosed
US-20100047367-A1 COMPOUNDS AND METHODS FOR THEIR USE FIBROGEN, INC. 2010-02-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100047367-A1 COMPOUNDS AND METHODS FOR THEIR USE HIF1AN, HIF1A, EGLN3 RIPK1 3787/4885ALDH1A1 268/4885KDM4E 471/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.